Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATEâ„¢
Phase 1
Completed
- Conditions
- Meningioma
- Interventions
- Drug: Cu-64 SARTATE and Cu-67 SARTATE
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 5
- Registration Number
- NCT03936426
- Locations
- 🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath